Cencora, Inc.
Leadership History
4 leaders · 2001 to present
Robert P. Mauch is the CEO of Cencora, in the role since 2024. The first chief executive was R. David Yost, from 2001.
| Name | Role | From | To | Years in role |
|---|---|---|---|---|
| Eva Boratto | Executive Vice President and Chief Financial Officer | 2026 | Present | < 1 |
| Robert P. Mauch | President and Chief Executive Officer | 2024 | Present | 2 |
| Steven H. Collis | Former Chief Executive Officer; Executive Chairman | 2011 | 2024 | 13 |
| R. David Yost | Former Chief Executive Officer | 2001 | 2011 | 10 |
Cencora sits between drug makers such as Pfizer, Merck and Eli Lilly and the pharmacies, hospitals and clinics that dispense medicine. Along with McKesson and Cardinal Health it handles the large majority of U.S. prescription drug distribution. It reports two segments, U.S. Healthcare Solutions (about $74.9 billion of revenue in the June 2026 quarter) and International Healthcare Solutions (about $7.7 billion), plus other businesses including MWI Animal Health. The company does not make drugs; its value lies in logistics, compliance, purchasing and services for manufacturers and providers. The company is headquartered in Conshohocken, Pennsylvania.
Cencora makes money on volume and services rather than markups alone. It buys medicines from manufacturers, holds them in a national network of distribution centers and delivers them, often overnight, to pharmacies, hospitals, clinics and physician offices. Revenue is enormous because the full drug price passes through its books, but adjusted gross margin is only around 4% (4.16% in the June 2026 quarter). Profit comes from distribution service fees paid by manufacturers, generic-drug sourcing, specialty distribution of oncology and other biologics, and services such as World Courier clinical-trial logistics, commercialization and market-access consulting, and management services organizations (MSOs) for retina and oncology practices.
Executive Vice President and Chief Financial Officer
2026 – Present
0 years (current)
Boratto managed the complex financial modeling required for AmerisourceBergen's massive $6.27 billion acquisition of Walgreens Boots Alliance's European distribution business.
As CFO, she oversaw the severe financial fallout and multi-billion dollar settlement payments resulting from the company's alleged role in the US opioid crisis.
President and Chief Executive Officer
2024 – Present
2 years (current)
Mauch became CEO on October 1, 2024, after serving as Executive Vice President and Chief Operating Officer and leading the U.S. distribution business. As CEO he has narrowed the company's focus around pharmaceuticals, completing the Retina Consultants of America and OneOncology acquisitions and agreeing to merge MWI Animal Health into Covetrus.
Former Chief Executive Officer; Executive Chairman
2011 – 2024
13 years
Collis rebranded the massive AmerisourceBergen conglomerate to 'Cencora' in 2023, attempting to distance the company from its heavily publicized involvement in the opioid epidemic.
As CEO, he successfully deepened the company's highly lucrative partnership with Walgreens, securing their long-term position as one of the three massive distributors controlling the US drug supply.
Former Chief Executive Officer
2001 – 2011
10 years
Yost architected the massive 2001 merger between AmeriSource Health and Bergen Brunswig, creating the modern AmerisourceBergen wholesale behemoth.
Serving as CEO until 2011, he aggressively transitioned the company from a regional drug wholesaler into a massive, national supply chain backbone for independent pharmacies and hospitals.
Cencora's main challenges are thin margins, heavy customer concentration (Walgreens remains its largest customer under a distribution agreement through 2029), manufacturer list-price cuts that shrink pass-through revenue, controlled-substance compliance, opioid settlement payments, cybersecurity risk after a 2024 data incident, and the integration and debt load from its RCA and OneOncology acquisitions.
Robert P. Mauch (Bob Mauch) became President and Chief Executive Officer of Cencora on October 1, 2024, succeeding long-time then-CEO Steven H. Collis.
Before becoming CEO, Bob Mauch was Cencora's Executive Vice President and Chief Operating Officer and led its U.S. pharmaceutical distribution business. He spent much of his career in operational leadership at AmerisourceBergen.
Steven H. Collis was President and CEO of AmerisourceBergen and Cencora from 2011 to 2024 and then became executive chairman. During his tenure revenue more than tripled. He also oversaw the Walgreens partnership, the World Courier and Alliance Healthcare acquisitions, and the 2023 Cencora rebrand.
R. David Yost served as the first Chief Executive Officer of AmerisourceBergen from its formation via merger in 2001 until his retirement in 2011. Yost successfully integrated the operations of AmeriSource and Bergen Brunswig, building a Fortune 20 healthcare distribution leader.
The 2023 rebrand to Cencora happened under CEO Steven Collis, with Bob Mauch as a senior operating executive. Mauch has led the company under the Cencora name since becoming CEO in October 2024.
Under Steven Collis and Bob Mauch, Cencora served as a primary distribution partner for the US government's COVID-19 therapeutic treatments (including monoclonal antibodies and antiviral medications), delivering life-saving therapies to hospitals nationwide without disruption.
Following the October 2024 transition, Steven H. Collis serves as Executive Chairman of the Board of Directors focusing on board governance and strategic stakeholder partnerships, while Bob Mauch leads global executive operations, enterprise growth, and commercial execution as CEO.
Mauch calls Cencora's strategy pharmaceutical-centric. The plan grows specialty distribution and physician services, including RCA and OneOncology, sharpens the portfolio through moves like the MWI-Covetrus merger, and returns cash through dividends and buybacks.
Steven Collis serves as CEO. He was responsible for massively expanding the company globally and navigating the severe legal fallout and multi-billion-dollar settlements associated with the opioid crisis.
Compare executive leadership tenures and strategic transitions
Explore Cencora
Core profile pages, founders and related research hubs for this company.